Yash Agarwal

PhD @MITdeptofBE ‘22 | @BU_Tweets BME ‘17 | Interests include Immunology, SynBio and Drug Delivery | he/him 🇮🇳/🇺🇸

[Yash Agarwal @yashagar7]

Excited to share what I’ve been upto over the past 4 years! Out @natBME today, we use the age-old clinical vaccine adjuvant alum to make cancer immunotherapy with IL-12 safer and more effective in various mouse cancer models. Let us know what you think!
https://t.co/RqpXvbZRrr

[Sean Fennessey @SeanFennessey]

Held onto all my stock. 📈

[Ankyra Therapeutics @ankyratx]

@ankyratx announces the first visceral tumor patient dosed
https://t.co/AuvBKMhsYG

#anchoredimmunotherapy
#anchoreddrugconjugates

[ron boger @ronboger]

congrats @CaitlynBioE and @TwoStepTx on the launch! https://t.co/YaMgrea2X9

[omri_drory @omri_drory]

My dad died from colon cancer in 2020, NFX bio principal Gita Bassman Reinitz lots two parents to cancer, so many people we know are effected by this horrible disease..

https://t.co/nXchuC7Mfz

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

We are thrilled to announce our latest investment in @TwoStepTx!

Read more about why we invested 👇

https://t.co/ERxSs6b8TB

💡 Enabling targeted delivery to virtually any solid tumor using a unique and modular polyspecific integrin-binding peptide.

👩‍💻 The Founder: @CaitlynBioE

📌 Location: San Francisco, CA

💰 Investment Stage: Seed

You can also read more in this article (shoutout to @ky_lahucik for the writeup!)

https://t.co/HY5Lc43zvT

[Yash Agarwal @yashagar7]

Thrilled to be part of the @TwoStepTx team!

Congrats to CEO @CaitlynBioE on spearheading this important vision as we work to develop targeted therapies for solid tumors.

More 👇

[TwoStepTx @TwoStepTx]

1/ We’re excited to announce our official launch and the closing of a $6.5M seed round to advance our pipeline of targeted therapies for solid tumors. Learn more 👉
https://t.co/wjSYaEhzEg

[Josh Peters @joshpetepeters]

we're kicking off another round of hiring at @joinprox across immunology, antibody engineering, or computational roles. if you know someone looking to join a flat, early-stage startup laser-focused on therapeutic development, DM me!

[Caleb Perez @calebrperez]

Excited to share some of my PhD work was pre-printed! Using single-cell sequencing, we took a deep look at a library of CAR signaling architectures to try to identify signal-intrinsic drivers of CAR-T function🧵👇 @MEBirnbaum @kochinstitute @MITdeptofBE

https://t.co/DHbwlFQlnB

[Yash Agarwal @yashagar7]

@LSantollani Beautiful work @LSantollani Glad to see it finally out there!

[Yash Agarwal @yashagar7]

Having my PhD work actually end up in human clinical trials was only ever a dream. Huge congratulations and thanks to the brilliant @ankyratx team for making it a reality!

[Polaris Partners @PolarisVC]

Congrats to the @ankyratx team on receiving FDA IND and Health Canada CTA approval. Read more about it here: https://t.co/epbbGMymSL

[Ankyra Therapeutics @ankyratx]

Exciting news today as we announce our clinical trial collaboration and supply agreement with @Merck  to assess ANK-101 in combination with Keytruda® (pembrolizumab) in patients with solid tumors.

Read more: https://t.co/WBfx4IMzWJ

[Brendan Horton @blhorton]

Excited to share that the second paper from my post-doc is out! This was a very fun 4-way collaboration between the @stefanispranger, White, and @TheWittrupLab labs at @MIT and the Garcia lab at @Stanford! @kochinstitute @MITBiology @sitcancerECS https://t.co/iZvhvDj42i

[Koch Institute at MIT @kochinstitute]

Join Koch Institute immune engineers and @ankyratx CEO Howard Kaufman on April 4 to hear how they are taking anchored immunotherapy against solid tumors from the lab bench to the cancer clinic.

Register: https://t.co/xypnI3sRok

[Nataliya Prokhnevska🇺🇦 @nataliya_pro_]

Really excited to share the work I have done with @HaydnKissick over my PhD! In this work we show that CD8 T cell activation and differentiation in cancer happens in two distinct phases. Tweet-orial below summarizes the main findings we have described. https://t.co/H6iR9kdIwU

[Ankyra Therapeutics @ankyratx]

Excited to present data on our IL-12 ANK-101 program @sitcancer Annual Meeting, which highlights the potential of our Anchor Immunotherapy Platform to overcome the limitations of traditional IL-12 to enhance it's therapeutic window to reach more patients
https://t.co/7bKGc1HQkx

[Wittrup Lab @TheWittrupLab]

Thanks @ACIR_org for this nice write up on our recent work leveraging alum anchoring technology to improve the therapeutic index of interferons!

[ACIR @ACIR_org]

Alum-anchoring #interferons to improve efficacy @kochinstitute Read our summary and interview with the researchers here => https://t.co/igFk6xFZdS

[Yash Agarwal @yashagar7]

The study demonstrates the strong benefits of intratumorally-retained type 1 IFNs in the B16F10 melanoma model while exploring the complicated relationship between combination immunotherapy and adaptive memory formation. Let us know what you think!

[Yash Agarwal @yashagar7]

Check out the next story in the intratumoral alum/cytokine saga spearheaded by the twitter-less Dr. Emi Lutz (now published @PNASNews) with critical contributions from @noor_M0MIN, @josephrpalmeri, and more from @TheWittrupLab, Spranger lab and Irvine lab

https://t.co/6KdGGmljRc

[Brittany Hartwell, PhD @Britt_Hartwell]

Very excited to share that our new article is out this week in @ScienceTM -- & is featured on the cover! A fitting cap to #ICMI2022!
https://t.co/UPvClGF2sB

This work from my postdoc in the IrvineLab @kochinstitute @MIT introduces an intranasal mucosal vaccine strategy that (1/)